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Objective: Homozygous loss-of-function mutations in the gene coding for the homeobox transcription factor (TF) PDX1 leads to pancreatic
agenesis, whereas heterozygous mutations can cause Maturity-Onset Diabetes of the Young 4 (MODY4). Although the function of Pdx1 is
well studied in pre-clinical models during insulin-producing b-cell development and homeostasis, it remains elusive how this TF controls
human pancreas development by regulating a downstream transcriptional program. Also, comparative studies of PDX1 binding patterns in
pancreatic progenitors and adult b-cells have not been conducted so far. Furthermore, many studies reported the association between
single nucleotide polymorphisms (SNPs) and T2DM, and it has been shown that islet enhancers are enriched in T2DM-associated SNPs.
Whether regions, harboring T2DM-associated SNPs are PDX1 bound and active at the pancreatic progenitor stage has not been reported
so far.
Methods: In this study, we have generated a novel induced pluripotent stem cell (iPSC) line that efﬁciently differentiates into human pancreatic
progenitors (PPs). Furthermore, PDX1 and H3K27ac chromatin immunoprecipitation sequencing (ChIP-seq) was used to identify PDX1 tran-
scriptional targets and active enhancer and promoter regions. To address potential differences in the function of PDX1 during development and
adulthood, we compared PDX1 binding proﬁles from PPs and adult islets. Moreover, combining ChIP-seq and GWAS meta-analysis data we
identiﬁed T2DM-associated SNPs in PDX1 binding sites and active chromatin regions.
Results: ChIP-seq for PDX1 revealed a total of 8088 PDX1-bound regions that map to 5664 genes in iPSC-derived PPs. The PDX1 target
regions include important pancreatic TFs, such as PDX1 itself, RFX6, HNF1B, and MEIS1, which were activated during the differentiation
process as revealed by the active chromatin mark H3K27ac and mRNA expression proﬁling, suggesting that auto-regulatory feedback
regulation maintains PDX1 expression and initiates a pancreatic TF program. Remarkably, we identiﬁed several PDX1 target genes that
have not been reported in the literature in human so far, including RFX3, required for ciliogenesis and endocrine differentiation in mouse,
and the ligand of the Notch receptor DLL1, which is important for endocrine induction and tip-trunk patterning. The comparison of PDX1
proﬁles from PPs and adult human islets identiﬁed sets of stage-speciﬁc target genes, associated with early pancreas development and
adult b-cell function, respectively. Furthermore, we found an enrichment of T2DM-associated SNPs in active chromatin regions from iPSC-
derived PPs. Two of these SNPs fall into PDX1 occupied sites that are located in the intronic regions of TCF7L2 and HNF1B. Both of these
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Original ArticleConclusions: Our data provide stage-speciﬁc target genes of PDX1 during in vitro differentiation of stem cells into pancreatic progenitors that
could be useful to identify pathways and molecular targets that predispose for diabetes. In addition, we show that T2DM-associated SNPs are
enriched in active chromatin regions at the pancreatic progenitor stage, suggesting that the susceptibility to T2DM might originate from imperfect
execution of a b-cell developmental program.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diabetes mellitus is a group of heterogeneous disorders characterized
by hyperglycemia and the progressive loss or dysfunction of the
insulin-producing b-cells in the pancreas. Today, over 415 million
people worldwide have been diagnosed with diabetes and the number
is expected to rise to 642 million by 2040 [1]. There are four main
types of diabetes mellitus: Type 1 Diabetes Mellitus (T1DM), Type 2
Diabetes Mellitus (T2DM), Gestational Diabetes and Maturity Onset
Diabetes of the Young (MODY).
The most common form of diabetes is T2DM, a multifactorial disease
that is caused by a complex interplay between genetic, epigenetic, and
environmental factors. This form predominantly occurs in adulthood
due to the failure of b-cells to produce sufﬁcient amounts of insulin for
maintenance of normoglycemia. For decades, analyses of natural
genetic variation have been used to understand the pathogenesis of
T2DM and to improve diagnosis and treatment for the people who
suffer from this disease [1,2].
MODY is inherited in an autosomal dominant fashion and presents
early in life due to defects in developing enough b-cells or failure in
function. There are at least 13 types of MODY that are diagnosed in 1e
2% of diabetes patients, which are caused by mutations in several
essential genes, such as GCK, HNF1A, HNF1B, and PDX1 [3].
Among these genes, PDX1 encodes one key TF, regulating b-cell
development and function [4,5]. In humans, the PDX1 gene is located
on chromosome 13q12.1 and encodes for a protein of 283 amino
acids. Typically for a TF it contains a transactivation domain and a
homeodomain that binds to DNA. In mouse, the expression of Pdx1 is
ﬁrst evident at embryonic day (E) 8.5e9.0 and becomes restricted to
b- and d-cells in adult islets [6e9]. Homozygous Pdx1 knockout mice
form pancreatic buds but fail to develop a pancreas [10]. On the
contrary, heterozygous Pdx1 knockout mice develop a pancreas but
become diabetic in adulthood and b-cells increasingly undergo
apoptosis [11e13]. In humans, PDX1 is expressed in the developing
pancreas and heterozygous mutations in the PDX1 gene cause a strong
form of monogenic diabetes, called MODY4 [14,15]. Contrary to the
numerous studies highlighting the importance of Pdx1 during mouse
pancreas development, little is known about the role of this TF in
human b-cell development, homeostasis and function. Speciﬁcally, it
is important to unravel the PDX1 target gene program to understand its
cell-type speciﬁc function during development and its contribution to
MODY and T2DM in adulthood. Genome-wide association studies have
identiﬁed multiple loci associated with the susceptibility to T2DM,
including TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, and IGF2BP2
[16,17]. It has been shown that islet enhancers are enriched in T2DM-
associated SNPs [18]; however, it is unknown if these SNPs affect
PDX1 bound cis-regulatory regions and play a role during pancreas
development.
Here, we generated a novel iPSC line from a healthy female donor and
conﬁrmed its efﬁcient in vitro pancreatic differentiation. We performed
transcriptome analysis combined with ChIP-seq proﬁling of active
H3K27ac histone modiﬁcations and PDX1 binding sites in PPs and
compared these to adult islets to investigate stage-speciﬁc functions of58 MOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. ThiPDX1 in progenitors and adult b-cells. Furthermore, through screening
for T2DM-associated SNPs in active chromatin regions of PPs, we
suggest that some SNPs might increase the diabetes risk by affecting
pancreas and b-cell development.
2. MATERIALS AND METHODS
2.1. Ethics statement
The choice of appropriate human donors and the procedures for skin
biopsy, isolation, and characterization of dermal ﬁbroblasts were
performed in accordance with study protocols approved by the Ethics
Committee of the Medical Faculty of the Eberhard Karls University,
Tübingen. The study design followed the principles of the Declaration
of Helsinki. All study participants gave informed consent prior to entry
into the study. All mice were housed in the facilities at the Helmholtz
Zentrum München e German Research Center for Environmental
Health (HMGU) and treated in accordance with the German animal
welfare legislation and acknowledged guidelines of the Society of
Laboratory Animals (GV-SOLAS) and of the Federation of Laboratory
Animal Science Associations (FELASA). The teratoma generation pro-
cedure was approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of HMGU and notiﬁed to the local regulatory supervisory
authority.
2.2. Skin biopsy, isolation, and characterization of dermal
ﬁbroblasts
A full-thickness skin specimen was taken by punch biopsy from the
upper arm in the deltoid muscle region. After removal of adipose tissue
remnants and visible blood vessels, the sample was digested overnight
at 4 C with 10 U/mL dispase II (Roche Diagnostics, Mannheim,
Germany) in 50 mM HEPES pH 7.4, 150 mM NaCl. Thereafter, the
digest was incubated for 30 min at 37 C under continuous shaking
(1200 rpm). Using forceps, the dermis was separated from the
epidermal layer, and ﬁbroblasts were isolated from the dermis by
digestion with 0.2% collagenase CLS I (Biochrom, Berlin, Germany) in
DMEM, 10% BSA for 45 min at 37 C under continuous shaking
(1200 rpm). For puriﬁcation of the ﬁbroblasts, the digest was ﬁltered
through a 70 mm mesh and centrifuged. The pelleted cells were
resuspended, grown for three days in DMEM, 10% FCS, and subse-
quently further expanded in Medium 106 supplemented with low
serum growth supplement (Invitrogen, Thermo Fisher Scientiﬁc, Wal-
tham, MA, USA). Samples of dermal ﬁbroblasts were tested for the
presence of viruses, pathogenic to humans, i.e., HBV, HCV, and HIV,
with Genesig PCR-based detection kits from Primerdesign Ltd.
(Chandler’s Ford, UK) and for the presence of mycoplasma with a PCR
test kit from PanReac AppliChem (Darmstadt, Germany) and, in par-
allel, by DNA staining with DAPI. All cultures were found to be negative
for the tested contaminants.
2.3. XM001 iPSCs generation
Primary ﬁbroblasts from a healthy female donor were reprogrammed
into pluripotent stem cells using a non-integrating Episomal iPSC
Reprogramming Kit (Invitrogen, Cat. no. A14703). This kit contains as is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mixture of three vectors, which have the oriP/EBNA-1 (EpsteineBarr
nuclear antigen-1) backbone that delivers six reprogramming factors:
OCT4, SOX2, NANOG, LIN28, KLF4, and L-MYC [20]. Human ﬁbro-
blasts, at 75e90% conﬂuency, were transfected using the Amaxa 4D-
Nucleofector transfection system and a nucleofector kit for human
dermal ﬁbroblasts (Lonza, Cat. no. VPD-1001), plated onto geltrex-
coated culture dishes and incubated in supplemented ﬁbroblast me-
dium. The ﬁbroblast medium contained knockout DMEM/F-12 (Life
Technologies), 10% ESC-qualiﬁed FBS (Life Technologies), 1% MEM
non-essential amino acids (Life Technologies), 10 mM HA-100 (Santa
Cruz) and 4 ng/mL bFGF (Life Technologies). At 24 h after transfection,
the medium was exchanged with N2B27 medium supplemented with
0.5 mM PD0325901 (Stemgent), 3 mM CHIR99021 (Stemgent), 0.5 mM
A-83-01 (Stemgent), 10 mM HA-100 (Santa Cruz), 10 ng/mL hLIF (Life
Technologies) and 100 ng/mL bFGF (Life Technologies). The basic
N2B27 medium contained DMEM/F12 with HEPES (Life Technologies),
1  N2 supplement (Life Technologies), 1  B27 supplement (Life
Technologies), 1% MEM non-essential amino acids, 1  Glutamax
(Life Technologies) and 1  b-Mercaptoethanol (Life Technologies).
On day 15 after transfection, the medium was changed to Essential 8
medium and monitored for the emergence of iPSC colonies. Around 3
weeks after transfection, undifferentiated iPSC colonies were picked
and transferred onto fresh geltrex-coated culture dishes for expansion.
2.4. XM001 iPSCs characterization
DNAwas extracted from iPSCs using standard procedure. Markers for the
episomal backbone were ampliﬁed by semi-quantitative PCR to exclude
transgene integration. Primers were as follows: oriP forward: TTCCAC-
GAGGCTAGTGAACC. oriP reverse: TCGGGGGTGTTAGAGACAAC; EBNA-1
forward: ATCGTCAAAGCTGCACACAG. EBNA-1 reverse: CCCAGGAGTCC-
CAGTAGTCA. For karyotype analysis, we used the cells growing in log-
arithmic phase. These were fed with freshmedium the day before adding
colcemid for 2 h. Cells were then trypsinized, treated with hypotonic
solution (0.075 M KCl) for 20 min, and ﬁxed with methanol:acetic acid
(3:1). Metaphases were spread on microscope slides, and chromosomes
were classiﬁed according to the International System for Human Cyto-
genic Nomenclature using the standard G banding technique. At least 20
metaphases were counted per cell line, and the ﬁnal karyotype was
stated if it was present inmore than 85% of them. For teratomas, 2 106
iPSCs were injected into the right hind leg of immunocompromised NOD/
SCID mice. Tumors were excised after 8 weeks, ﬁxed, embedded in
parafﬁn, sectioned and stained with hematoxylin/eosin [51].
2.5. XM001 iPSCs culture
XM001 iPSCs were cultured on 1:100 diluted Matrigel (BD Biosciences)
in mTeSR1 medium (Stem Cell Technologies). At w70e80% con-
ﬂuency, cultures were rinsed with 1  DPBS without Mg2þ and Ca2þ
(Invitrogen) followed by incubation with 1 TrypLE Select Enzyme (Life
Technology) for 3e5 min at 37 C. Single cells were rinsed with
mTeSR1 medium, and spun at 1,000 rpm for 3 min. The resulting cell
pellet was resuspended in mTeSR1 medium supplemented with
10 mM Y-27632 (SigmaeAldrich) and the single cell suspension was
seeded atw1.5 105 cells/cm2 on Matrigel-coated surfaces. Cultures
were fed every day with mTeSR1 medium and differentiation was
initiated 48 h following seeding, resulting inw90% starting conﬂuency.
2.6. Pancreatic progenitor differentiation
2.6.1. S1: Deﬁnitive endoderm (3 d)
XM001 iPSCs plated on 1:100 diluted Matrigel were ﬁrst rinsed with
1  DPBS without Mg2þ and Ca2þ (Invitrogen) and then cultured inMOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comRPMI 1640 medium (Invitrogen) further supplemented with 1.2 g/L
sodium bicarbonate (Sigma), 0.2% ESC-qualiﬁed FBS (Life Technolo-
gies), 100 ng/mL Activin-A (R&D Systems), and 20 ng/mL of Wnt3A
(R&D Systems) for day 1 only. For the next 2 days, cells were cultured
in RPMI with 0.5% FBS, 1.2 g/L sodium bicarbonate and 100 ng/mL
Activin-A.
2.6.2. S2: Primitive gut tube (3 d)
Cells were rinsed with 1  DPBS (without Mg2þ and Ca2þ) once and
then exposed to DMEM-F12 (Life Technologies) medium further sup-
plemented with 2 g/L sodium bicarbonate, 2% FBS and 50 ng/mL of
FGF7 (R&D Systems) for 3 days.
2.6.3. S3: Pancreatic progenitors (PP)/posterior foregut (4 d)
Cultures were maintained for 4 days in DMEM-HG medium (Life
Technologies) supplemented with 0.25 mM SANT-1 (SigmaeAldrich),
2 mM retinoic acid (RA; SigmaeAldrich), 100 ng/mL of Noggin (R&D
Systems), and 1% B27 (Invitrogen).
2.7. Immunoﬂuorescence imaging
Cells were ﬁxed with 4% paraformaldehyde for 30 min and then
permeabilized in PBS containing 0.2% Triton X-100. Cells were
blocked with PBS containing 3% BSA, and incubated with primary
antibodies overnight at 4 C. Then secondary antibodies were incu-
bated for 1 h at room temperature after washing with PBS. Images
were acquired on a TCS SP5 laser-scanning microscope (Leica). The
following antibodies and dilutions were used: goat anti-OCT-3/4
(1:500, #sc-8628, Santa Cruz), goat anti-SOX2 (1:500, #sc-17320,
Santa Cruz), mouse anti-TRA-1-60 (1:1000, #4746, Cell Signaling),
mouse anti-TRA-1-81 (1:50, MAB4381, Millipore), mouse anti-SSEA4
(1:500, #4755, Cell Signaling), rabbit anti-FOXA2 (1:250, #8186, Cell
Signaling), goat anti-SOX17 antibody (1:500, #GT15094, Acris/Novus),
goat anti-PDX1 antibody (1:500, #AF2419, R&D Systems).
2.8. Flow cytometry
Cells were dissociated using 1  TrypLE Select Enzyme and washed
with cold FACS buffer (5% FBS in 1 DPBS). Cells were ﬁxed with 4%
paraformaldehyde and permeabilized with donkey block solution (0.1%
tween-20, 10% FBS, 0.1% BSA and 3% donkey serum) containing
0.5% saponin. The cells were incubated with goat anti-SOX17 antibody
(1:500, #GT15094, Acris/Novus) and goat anti-PDX1 antibody (1:500,
#AF2419, R&D Systems) for 30 min at room temperature and then
stained with Alexa Fluor 555-conjugated donkey antibody directed
against goat (1:500, #A21432, Invitrogen) for 30 min at room tem-
perature. Flow cytometry was performed using FACS-Aria III (BD
Bioscience). FACS data were analyzed using FlowJo.
2.9. RNA isolation and qPCR
Total RNA was extracted from cells with the miRNeasy mini kit (Qiagen).
cDNA synthesis was performed with a high-capacity RNA-to-cDNA kit
(Applied Biosystems). TaqMan qPCR was performed under standard
conditions using ViiA7 (Applied Biosystems) and TaqMan Fast Advanced
Master Mix (Applied Biosystems). Samples were normalized to house-
keeping genes 18S ribosomal RNA (RN18S) and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Taqman probes (Applied Bio-
systems): PDX1, Hs00236830_m1; SOX9, Hs01001343_g1; PTF1A,
Hs00603586_g1; HNF1B, Hs01001602_m1; OCT4, Hs00999632_g1;
NANOG, Hs04260366_g1; GAPDH, Hs02758991_g1; 18S,
Hs99999901_s1; NKX6.1, Hs01055914_m1; NKX2.2, Hs00159-
616_m1.n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 59
Original ArticleSYBR qPCR was performed under standard conditions using ViiA7
(Applied Biosystems) and SYBR Green PCR Master Mix (Applied
Biosystems). Samples were normalized to the housekeeping gene
ACTB. Primers were as follows:
HHEX forward: ACGGTGAACGACTACACGC.
HHEX reverse: CTTCTCCAGCTCGATGGTCT;
MEIS1 forward: GGGCATGGATGGAGTAGGC.
MEIS1 reverse: GGGTACTGATGCGAGTGCAG;
ONECUT1 forward: GAACATGGGAAGGATAGAGGCA.
ONECUT1 reverse: GTAGAGTTCGACGCTGGACAT;
RFX6 forward: AAGCAGCGGATCAATACCTGT.
RFX6 reverse: ACCGTGGTAAGCAAACTCCTT;
ACTB forward: CCCAGAGCAAGAGAGG.
ACTB reverse: GTCCAGACGCAGGATG.2.10. ChIP-seq
XM001 PP cells (2 106 cells) were cross-linked in 1% formaldehyde
in culture medium for 10 min at room temperature. The cross-linking
reaction was stopped by the addition of glycine to a ﬁnal concentration
of 125 mM. For chromatin fragmentation, cells were resuspended in
lysis buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.5% SDS) and
sonicated in a Covaris S220 sonicator with a duty cycle of 2%, a peak
incident power of 105 W and 200 cycles per burst for 20 min. The
fragmented chromatin was diluted 1:5 in IP-Buffer (10 mM Tris-HCl
(pH 7.5), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% SDS,
0.1% Na-Desoxycholate, 140 mM NaCl, H2O, Protease Inhibitors) and
directly used for immunoprecipitation. For PDX1 ChIP, 60% of the
chromatin (equivalent of 1.2 106 cells) was processed in two parallel
ChIPs using magnetic beads, preloaded with 3 ml goat anti PDX1
antibody (kindly provided by C. Wright), for each ChIP. For H3K27ac
ChIP, 40% of the chromatin (equivalent 0.4  106 cells) was pro-
cessed in three parallel IPs using magnetic beads, preloaded with 3 mg
anti H3K27ac antibody (Diagenode, C15410174). For all ChIPs, anti-
body incubation was performed at 4 C for 5 h. Beads were then
washed 5 times using (1.) IP-Buffer, (2.) Washing-Buffer 1 (500 mM
NaCl, 50 mM Tris-HCl (pH 8.0), 0.1% SDS, 1% NP-40), (3.) Washing-
Buffer 2 (250 mM LiCl, 50 mM Tris-HCl (pH 8.0), 0.5% Na-
Deoxycholate, 1% NP-40) and (4. & 5.) Washing-Buffer 3 (10 mM
Tris-HCl (pH 8.0), 10 mM EDTA). Subsequently, protein-DNA com-
plexes were eluted from the beads in Elution-Buffer (50 mM Tris-HCl
(pH 8.0), 10 mM EDTA, 1% SDS) at 65 C for 20 min. Cross-links
were reversed at 65 C overnight, and DNA was puriﬁed for library
construction with the MicroPlex kit (Diagenode, C05010010). Libraries
were sequenced on an Illumina HiSeq 1500 (50 bp, single end).
2.11. ChIP-seq data analysis
Raw reads from PDX1 and H3K27ac ChIP-seq were processed with
Trimmomatic (0.35) to remove low quality bases and potential adapter
contamination. Next, reads were aligned to hg19 genome using
bowtie2 (2.2.6) with very-sensitive option and duplicate reads were
removed using samtools (1.3). Binding sites for PDX1 were then called
using GEM [52] and ﬁltered, after visual inspection, using a Q-value
cut-off of 104 and overlapping regions were merged. Regions of
H3K27ac enrichment were called using BCP-HM [53] with default
parameters. PDX1 binding sites and H3K27ac enriched regions were
further ﬁltered by removing blacklist regions [54]. Regions and binding
sites within 20 kb of a TSS or within a gene body were annotated with
the respective gene using bedtools (2.26.0). Motif analysis, annota-
tions with genomic features, and pathway enrichment analysis were60 MOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. Thiperformed using HOMER [55]. For publicly available data sets, raw
reads were downloaded from online repositories and processed as
described above (GSE54471 [22], GSE58686 [24], E-MTAB-1143 [28],
E-MTAB-1919 [18]). For clustering of H3K27ac proﬁles, ﬁrst the reads
that fall in the intersection of enriched regions from all samples to be
compared were counted and normalization factors were calculated
using DESeq2. Next, the union of all identiﬁed regions from all samples
to be compared was merged and reads falling into these regions were
counted. Reads were then processed with DESeq2 using normalization
factors calculated before and normalized read counts were used to
calculate Pearson correlation coefﬁcients that were subsequently
subjected to hierarchical clustering. To calculate enrichment of
H3K27ac at PDX1-bound sites, three sets of random sites were
generated by shufﬂing all 8088 PDX1 binding sites using bedtools
(2.26.0) shufﬂe. Then, H3K27ac reads were counted and the ratio of
the mean read count at PDX1 sites over the mean read count at
shufﬂed sites was calculated. For visualization, BIGWIG ﬁles, normal-
ized to 1  sequencing depth (Reads Per Genomic Content) using
deepTools bamCoverage, were used. H3K27ac and PDX1 tracks for
adult islets were generated from merged BAM ﬁles containing reads
from all available experiments. To generate high conﬁdence PDX1
binding sites, the overlap of PDX1 sites from progenitor proﬁles
(XM001, [22,24]) or islet proﬁles [18,28] was calculated, and sites
found in two out of three progenitor data sets or three out of four islet
data sets were considered as high conﬁdence binding sites.2.12. Enrichment of T2DM SNPs
To obtain positions and disease association P-values of T2DM-
associated SNPs, DIAGRAM 1000G GWAS meta-analysis Stage 1
Summary statistics [17] was downloaded and ﬁltered to remove all
SNPs with an association P-value below 5  108. For islet H3K27ac,
the union of enriched regions from all 3 available experiments [18,22]
was generated and subsequently, regions closer than 1000 bp were
merged. Enrichment P-values were calculated using bedtools (2.26.0)
ﬁsher and the SNPs overlapping regions of interest were identiﬁed
using bedtools (2.26.0) intersect. SNPs within 20 kb of a TSS or within
a gene body were annotated with the respective gene using bedtools
(2.26.0).2.13. Affymetrix microarray
For gene proﬁling, total RNA was extracted using miRNeasy Mini kit
(Qiagen, #217004), RNA integrity was checked using Agilent 2100
Bioanalyzer (Agilent RNA 6000 Pico Kit), and cDNA was ampliﬁed with
the Ovation PicoSL WTA System V2 (Nugen, 3312) in combination with
the Encore Biotin Module (Nugen, USA). Ampliﬁed cDNA was hy-
bridized on GeneChip Human Gene 2.0 ST arrays (Affymetrix,
902113). Expression console (v.1.3.0.187, Affymetrix) was used for
quality control. All subsequent computational analysis was performed
in R using Bioconductor packages. Expression data were RMA
normalized using the oligo package (version 1.38.0) and probe sets
were annotated using the package hugene20sttranscriptcluster.db
(version 8.5.0). Differential expression analyses were performed using
the limma package (version 3.30.7) and P-values were adjusted for
multiple testing by Benjamini-Hochberg correction. A gene was
considered as differentially expressed if the adjusted p-value (FDR)
was below a threshold of 0.05 and the fold-change was greater than
or equal to 2. Functional enrichments were conducted using HOMER
[55]. Gene set enrichment analysis was performed using GSEA 3.0
[56,57] with genes ranked by log2 ratio between XM001 PPs and
XM001 iPSCs.s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Efﬁcient differentiation of XM001 iPSCs into pancreatic progenitors. (A) Schematic of iPSC-derived pancreatic progenitor differentiation protocol. (B) Immuno-
staining for FOXA2 and SOX17 on day 3. Scale bar indicates 50 mm. (C) Representative FACS plot of SOX17þ cells at DE stage. A differentiated sample stained with only the
secondary antibody and XM001 iPSCs were used as negative controls. (D) FACS quantiﬁcation of the percentage of SOX17þ cells at DE stage (n ¼ 3). (E) Immunostaining for PDX1
on day 10. Scale bar indicates 50 mm. (F) Representative FACS plot of PDX1þ cells at the PP stage. A differentiated sample stained with only the secondary antibody and XM001
iPSCs were used as negative controls. (G) FACS quantiﬁcation of the percentage of PDX1þ cells at PP stage (n ¼ 3).
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Original Article2.14. Accession number
Microarray and ChIP-seq data have been submitted to the GEO data-
base at NCBI under the accession number GSE106950.
3. RESULTS
3.1. Efﬁcient differentiation of XM001 iPSCs into pancreatic
progenitors
To generate the XM001 induced pluripotent stem cell (iPSC) line, pri-
mary adult skin ﬁbroblasts from a healthy female donor were
reprogrammed into iPSCs by transfection with three episomal plasmids
encoding human OCT4, SOX2, NANOG, LIN28, KLF4, and L-MYC.
(Suppl. Figure 1A) [19,20]. We established the reprogramming protocol
including three stages: transfection, reprogramming and expansion
(Suppl. Figure 1B). Colonies with stem cell-like characteristics
appeared around day 15 post-infection and were handpicked by day 21
and subjected to quality controls. XM001 iPSCs were episomal vector
integration-free and of normal karyotype (Suppl. Figure 1CeD). Next,
we conﬁrmed the expression of several pluripotency markers (TRA-1-
60 and TRA-1-81, SSEA-3, and SSEA-4) and pluripotency TFs (OCT4
and SOX2) by immunostainings in XM001 iPSCs (Suppl. Figure 2). To
rigorously demonstrate multi-lineage potency of the generated iPSC
line, we injected 2  106 iPSCs subcutaneously into None-obese
diabetic/severe combined immunodeﬁciency (NOD/SCID) mice to
generate teratomas. The histological analysis of the induced teratomas
revealed that tissues from all three germ layers were differentiated,
conﬁrming pluripotency of our XM001 iPSCs in vivo (Suppl. Figure 3).
These data show successful reprogramming of ﬁbroblasts into
pluripotent iPSCs that stably display human embryonic stem cell
(hESC)-like characteristics and multi-lineage potency.
Next, we differentiated XM001 iPSCs into pancreatic progenitors (PP)
using a previously established protocol recapitulating pancreas
development through three main stages: deﬁnitive endoderm (DE),
primitive gut tube (GT), and PPs of the posterior foregut (Figure 1A)Figure 2: mRNA proﬁles of XM001 PPs show expression of pancreas speciﬁc gene
microarray data obtained from XM001 iPSCs and PPs. Genes with signiﬁcantly different exp
depicts increased expression in PPs, whereas brown depicts increased expression in iPSCs
from differentially expressed genes, shown in (A). (C) Gene set enrichment analysis of p
endocrine (E) and stem cell (F) related genes in XM001 iPSCs and PPs (n ¼ 3).
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and PP (PDX1) stages were veriﬁed by immunostaining and ﬂow
cytometry at day 3 and 10, respectively. At the DE stage, cells co-
expressed FOXA2 and SOX17 (Figure 1B) and ﬂow-cytometry anal-
ysis showed that approximately 95% of the cells were positive for the
DE marker SOX17 (Figure 1CeD). At the PP stage, the number of
PDX1-positive cells was around 85% as measured by ﬂow cytometry
and shown by immunostaining (Figure 1EeG).3.2. mRNA proﬁles of XM001 PPs show expression of pancreas
speciﬁc genes
To characterize global gene expression changes during PP differenti-
ation, we performed Affymetrix microarray analysis on XM001 cells at
the pluripotency and PP stages. In total, we identiﬁed 2658 differen-
tially expressed genes between iPSCs and PPs (FC  2, FDR  5%),
including important pancreatic genes such as HNF1B, SOX9, ONE-
CUT1, HHEX, FOXA2 and RFX6 that are upregulated in PPs, as well as
pluripotency-associated genes including NANOG and SOX2 that are
speciﬁcally expressed in iPSCs and downregulated in PPs (Figure 2A).
Moreover, gene set enrichment analysis as well as unbiased gene
ontology (GO) term and pathway analysis showed signiﬁcant enrich-
ment of terms associated with pancreas development in PP cells, while
terms associated with embryonic stem cells, cell cycle and prolifera-
tion were downregulated during the differentiation process
(Figure 2BeC). To verify the microarray results, we validated
expression changes of important genes involved in pancreas devel-
opment (HHEX, HNF1B, MEIS1, ONECUT1, PDX1, PTF1A, RFX6, and
SOX9), endocrine formation (NKX2-2, NKX6-1) and stem cell mainte-
nance (NANOG, OCT4) by quantitative PCR (qPCR) (Figure 2DeF).
Taken together, the XM001 iPSCs were efﬁciently differentiated into
PPs after 10 days of in vitro differentiation characterized by the
expression of lineage-speciﬁc genes and the downregulation of plu-
ripotency genes.s. (A) MA plot showing the mean log2 expression against the log2-fold change of the
ression (log2 fold change  1 and adjusted p-value  0.05) are drawn in color. Green
. (B) Bar graph of p-values from selected GO terms and KEGG and Reactome pathways
ancreas related GO terms. (DeF) qPCR validation of the expression of pancreas (D),
s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Correct speciﬁcation of tissue-speciﬁc enhancers is crucial for the
differentiation of individual cell types [22]. In this context, the histone
modiﬁcation H3K27ac is strongly associated with active enhancers and
promoters [23]. Therefore, we analyzed this histone modiﬁcation in
XM001 cells after 10 days of differentiation using chromatin immu-
noprecipitation followed by next generation sequencing (ChIP-seq) and
found that key pancreatic genes are marked by an active chromatin
conﬁguration. Wang et al. [22] thoroughly characterized the active
H3K27ac chromatin mark at several stages of pancreatic endoderm
differentiation (embryonic stem cells (ESCs), deﬁnitive endoderm (DE),
gut tube (GT), posterior foregut (FG; corresponds to PP stage of this
study) and late pancreatic progenitors/pancreatic endoderm (PE)) and
showed that the chromatin state at lineage-speciﬁc enhancers is vital
for developmental competence [22]. We used H3K27ac proﬁles from
hESC in vitro differentiations into pancreatic progenitors [22] to
compare with our H3K27ac proﬁle from differentiated XM001 iPSCs.
Unsupervised hierarchical clustering showed that after 10 days of
differentiation, the active chromatin landscape in XM001 iPSCs was
reminiscent of that in FG and PE stage derived from hESCs, indicating
that our iPSC-derived PPs represent an early stage of pancreas
development, shortly after PDX1 induction (Suppl. Figure 4).
3.3. Characterization of PDX1 binding in XM001 PP cells
Due to the crucial role of PDX1 in the speciﬁcation and differentiation of
the pancreatic lineages, characterization of its transcriptional targets is
important to understand human pancreas development. To do so, we
employed ChIP-seq analysis of PDX1 to proﬁle genome-wide PDX1
binding sites in XM001 iPSCs after 10 days of differentiation, a time
point at which PDX1 is robustly expressed in approximately 85% of
differentiated cells (Figure 1G). We identiﬁed a total of 8088 PDX1-
bound regions that are associated with 5664 genes which have
PDX1 binding sites within 20 kb of their TSS or within their gene body.
These include PDX1 itself and other pancreatic genes, such as RFX6,40
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www.molecularmetabolism.comMEIS1, and the MODY gene HNF1B (Figure 3A). Moreover, the active
histone modiﬁcation H3K27ac was enriched at the PDX1-bound sites
(Figure 3B and Suppl. Figure 5), which were predominantly found in
intergenic (44.2%) and intronic (40.4%) regions. However, with 11.3%
of the binding sites occurring in promoter regions, PDX1 was enriched
at the transcription start sites (TSS) of its target genes (Figure 3CeD).
De novo motif analysis was used to discover enriched motifs within
peak regions. The most signiﬁcantly enriched motif was found in
around 62% of all peak sequences and matched the PDX1 consensus
motif, conﬁrming the efﬁciency and speciﬁcity of the PDX1 ChIP-seq
approach (Figure 3E). We also compared our data to previous pub-
lished datasets of PDX1 ChIP-seq from hESC in vitro-derived PPs
[22,24] and found that the proﬁles of PDX1 binding show obvious
differences that might reﬂect hESC and iPSC differences, genetic
background variations and differences in the in vitro differentiation
stage or protocol (Suppl. Figure 6).
3.4. Functional characterization of PDX1-bound genes
Next, we examined the expression levels and function of PDX1-
bound genes in XM001 PP cells. From the 5664 PDX1-bound
genes, 4523 were covered by the microarray. In XM001 PP cells,
755 PDX1-bound genes were differentially expressed between the
iPSC and PP stage, which accounts for 28.4% of the total differ-
entially expressed genes (Figure 4AeB). Notably, we found up-
regulation of RFX3 and DLL1 among PDX1-bound genes during the
differentiation process. The mouse orthologues of these genes are
known to be involved in endocrine differentiation [25e27], sug-
gesting a potential role of these genes also during human pancreas
development. GO term analysis revealed an association of PDX1-
bound genes enriched in XM001 PP cells with pancreas, endocrine
and b-cell development as well as Notch and Hippo signaling,
suggesting that PDX1 induces a pancreatic program and primes for
endocrine differentiation (Figure 4C).−1500 0 1500
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Figure 4: Functional characterization of PDX1-bound genes. (A) Venn diagram depicting the overlap of PDX1-bound genes and the differentially expressed genes identiﬁed by
microarray analysis. (B) MA plot showing the log2 fold change over the mean log2 expression of PDX1-bound genes. Differentially expressed genes are displayed in color. Green
indicates enrichment in PPs, whereas brown indicates enrichment in iPSCs. (C) Bar chart of log10 p-values from enriched GO terms and KEGG and Reactome pathways of PDX1-
bound genes upregulated in PPs. (D) Venn diagram showing the overlap of high conﬁdence PDX1 binding sites from adult human islets and PPs and some annotated genes. (E) Bar
chart of log10 p-values from enriched gene ontology and KEGG/Reactome pathways from genes bound in adult islets and/or PPs.
Original ArticleBased on the tempo-spatial pattern of Pdx1 expression in mouse that
shows ubiquitous expression in all pancreatic progenitors and
restricted expression in mature b- and d-cells, we hypothesized that
the molecular programs controlled by Pdx1 might be stage speciﬁc. To
understand if PDX1 carries out different functions during development
and in adult b-cells, we compared PDX1 binding sites from PPs and
adult human islets. To that end, we derived a set of high conﬁdence
PDX1 binding sites for PPs and adult islets, comprised of PDX1 sites,
consistently bound in multiple datasets from this study and previous
studies from hESC-derived PPs and islets cells [18,22,24,28]. Of the
4978 high conﬁdence binding sites in PP cells, 1018 (20.4%) were
identiﬁed in the islet binding data (Figure 4D). This indicates that in PP
cells and adult islets only a minority of PDX1 binding sites are
conserved, while the majority of sites change during the differentiation
and maturation processes. Correspondingly, among the genes near
PP-speciﬁc high conﬁdence binding sites, we found important genes
for pancreas development, such as GATA4, HES1, HHEX, HNF1A,
NEUROG3, ONEUCUT1, TBX1, and YAP1, while genes near islet-
speciﬁc binding sites, including GLPR1, KCNJ11, SLC2A2, NKX6-1,
and MAFA, are associated with mature b-cell functions, e.g. insulin
secretion, glucose sensing and b-cell maturation and identity64 MOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. Thi(Figure 4DeE). Genes in the vicinity of shared binding sites are
implicated in endocrine development and include NKX2-2, PAX4,
RBPJ, and TGFB1. Of note, we also observed genes that show stage-
speciﬁc binding of PDX1 that can occur in combination with common
binding sites. These include HNF1B, RFX3, and RFX6, MNX1, FOXA2,
the MEG3 locus, and other important pancreatic genes (Figure 5C and
Suppl. Figure 7). Together, these results suggest that PDX1 binding
sites change during the process of pancreas and endocrine cell
development to meet the functional requirements of the different
stages during development and homeostasis.
3.5. Analysis of T2DM SNPs in XM001 PPs and adult islets
In a worldwide effort, genome-wide association studies (GWAS)
identiﬁed more than 300 genes that are linked to T2DM [29]. Of these
genes, 104 (32%) were bound by PDX1 in XM001 PPs. While harsh
mutations in MODY genes lead to monogenic forms of diabetes, an
increased susceptibility to T2DM is linked to SNPs occurring mostly in
non-coding regions. Moreover, it has been shown that islet enhancers
are enriched in T2DM-associated SNPs [18,30]. Therefore, we
analyzed whether XM001 PP active chromatin regions, as determined
by enrichment of H3K27ac, are also enriched in T2DM-associateds is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: Analysis of T2DM SNPs in XM001 PPs and adult islets. (A) Venn diagram depicting the overlap of T2DM SNPs found in active regions of adult islets and XM001 PPs.
(B) P-values of T2DM SNPs near known T2DM-associated genes found in active regions of adult islets [18,22] and XM001 PPs. P-values of SNPs bound by PDX1 in PPs and islets
are shown as black circles and triangles, respectively. (C) ChIP-seq data tracks showing H3K27ac and PDX1 from PP and islet [18,22,28] cells at the HNF1B locus. The SNP
rs11263763 is located in a PP speciﬁc PDX1 binding site in the ﬁrst intron of HNF1B. The PP speciﬁc enhancer regions are shaded in gray.SNPs and if there are different variants in XM001 PPs and adult islets.
To this end, we used the DIAGRAM 1000G GWAS meta-analysis data
[17] and identiﬁed SNPs with a high association signiﬁcance (1788
SNPs, P  5  108) that overlap with active chromatin marks in
XM001 PPs and adult islets [18,22]. We found a signiﬁcant enrich-
ment of T2DM-associated SNPs in active chromatin of both PPs (437
SNPs, P ¼ 1.0156  10106) and islets (918 SNPs,
P ¼ 8.2266  10263). Closer examination of the enriched SNPs
showed that of the 918 SNPs found in islet active chromatin, 380 fall
in regions that are also enriched in H3K27ac in the XM001 PP cells.
However, we could also identify 57 SNPs in regions, active specif-
ically in PPs (Figure 5A). When we mapped the SNPs to genes, we
identiﬁed 857 SNPs in the vicinity of known genes (20 kb up-/
downstream of or within a gene body), and these included mostly
known T2DM-associated genes, e.g. TCF7L2, IGF2BP2, HNF1B, and
FTO (Figure 5B). While most of these genes were associated with
SNPs in regulatory regions active in PP and islets, some genes were
associated with SNPs in cell type-speciﬁc active regions. SNPs in
islet-speciﬁc regions were found near the genes FTO, HNF1A,
KCNJ11, PPP2R2C, and SYN2 and SNPs in PP-speciﬁc regions near
SYN2, IGF2BP2, KIF11, and PPARG. Of note, the PPARG locus is the
only T2DM locus were a T2DM-associated SNP falls exclusively into a
PP-speciﬁc active region and that does not have any T2DM-
associated SNP in a commonly active or islet-speciﬁc active site.
The enrichment of T2DM SNPs in active regulatory regions of PP cells
raises the possibility that the susceptibility to T2DM is, at least inMOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comparts, already established during pancreatic development, possibly
through miss-regulation of key genes and developmental programs.
Interestingly, when overlapping the disease-associated SNPs with
PDX1 binding sites in PP and islet cells, we found only six SNPs that lie
in the PDX1-bound sites (3 SNPs in PP PDX1 sites and 3 SNPs in islet
PDX1 sites) (Figure 5B). The SNP rs8044769, SNP rs78681698 and
SNP rs150111048 are in PDX1-bound regions in islets and are near
FTO, THADA, and IGF2BP2. Another 3 SNPs near HNF1B and TCF7L2
are found in PDX1-bound regions of PP cells. At the HNF1B locus, the
SNP rs11263763 is located in a PP-speciﬁc PDX1 binding site in the
ﬁrst intron of HNF1B (Figure 5C). In addition, there are PP-speciﬁc
active enhancer regions, in the 4th intron and downstream of
HNF1B, suggesting that HNF1B might be regulated in different ways
during development and adulthood. At the TCF7L2 locus, the SNPs
rs12762233 and rs7087006 are located in PP-speciﬁc PDX1 binding
sites that may regulate TCF7L2 expression during development. SNPs
near the TCF7L2 locus have the highest association to T2DM and
mutations of HNF1B can cause MODY5. Thus, mutations in cis-
regulatory regions of these genes may predispose to diabetes. This
further supports the notion that the risk for T2DM might be linked to
early pancreas development.
4. DISCUSSION
Even though, a recent study conﬁrmed that the key events of
pancreatic endocrine cell formation in vivo are mimicked during in vitron access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 65
Original Articledifferentiation [31], the efﬁcient generation of functional and mature b-
cells for cell-replacement therapy of diabetes still remains a challenge
[32e34]. To produce such functional cells fulﬁlling the physiological
properties of mature islets, it is important to understand the molecular
mechanisms and gene regulatory networks governing the speciﬁcation
of early human pancreatic lineages that later differentiate into func-
tional b-cells. In this context, understanding the temporal progression
of key pancreatic TF target genes during development is valuable in-
formation that helps to better recapitulate the developmental steps
required for the differentiation of functional b-cells in vitro. However,
the access to primary human material of early pancreas development
is very limited and thus, in vitro approaches have to be employed to
study these early steps in a human system.
Although it is well known that Pdx1 plays a crucial role during mouse
pancreas development, its stage-speciﬁc role in human pancreatic
progenitors and adult b-cells has not been thoroughly studied. To
address this question, we combined integrated analysis of genome-
wide PDX1 binding sites and H3K27ac together with mRNA proﬁling
in PPs derived from a novel human iPSC line.
Global characterization of PDX1 binding sites in iPSC-derived PPs iden-
tiﬁed numerous target sites and associated genes, including develop-
mental regulatory factors, signaling molecules and factors important for
mature b-cell function as well as many of the genes, differentially
expressed between iPSCs and PPs. To our knowledge, this is the ﬁrst
genome-wide characterization of PDX1 binding in iPSC-derived PPs and
comparison with previous PDX1 datasets from hESC-derived PPs of
similar stages shows signiﬁcant differences in PDX1 binding [22,24].
There are many possible explanations for this discrepancy in PDX1
binding, including differences in the efﬁciency of differentiation, factors
used in the in vitro differentiation protocol, and the exact developmental
stage at the time of the experiments. This could explain many of the
differences between the XM001 data from this study and the data from
Wang et al. [22], as these cells are slightly further in development and
already express NKX6.1. Moreover, the developmental competence of a
given cell line has implications on the differentiation of the cells andmight
favor a set of target sites over another. Despite the differences, however,
sites bound by PDX1 in multiple datasets are useful to identify high
conﬁdence stage-speciﬁc target genes.
Among the PDX1-bound genes were RFX3 and DLL1 that are important
for mouse pancreas development [25e27]. RFX3 is a member of the
regulatory factor  family of transcription factors that contain a highly
conserved winged helix DNA-binding domain [35]. It has been shown
that Rfx3 is required for the differentiation and function of mature b-
cells and regulates the expression of the glucokinase gene in mice [25].
DLL1 is a member of the delta/serrate/jagged family of Notch ligands.
Mice deﬁcient for the Delta-like 1 gene (Dll1) show increased expres-
sion of Ngn3, which, in turn, causes an accelerated and increased
commitment to the endocrine lineage and depletes the progenitor pool,
ultimately leading to pancreatic hypoplasia [26,27]. Whether these
genes play important roles in human pancreas development has not
been characterized. Therefore, our analysis suggests a possible
evolutionary conserved function of RFX3 and DLL1 during human
pancreas development. In contrast, other PDX1-bound genes such as
TIMP2,MAFB, and SIX2, are known to be speciﬁcally express in human,
but not in mouse b-cells [36,37]. To address the function of newly
identiﬁed PDX1 target genes during development, the XM001 iPSCs has
been modiﬁed to express CRISPR/Cas9 under the control of an inducible
promoter, which will allow gene functional studies in the future [38].
PDX1 is a master regulator of early pancreatic development and is
expressed in all PPs in vivo but becomes restricted to b-and d-cells
during later stages of endocrine differentiation. Therefore, it is likely, that66 MOLECULAR METABOLISM 9 (2018) 57e68  2018 The Authors. Published by Elsevier GmbH. ThiPDX1 has different functions and targets at different stages of devel-
opment. When we compared genome-wide PDX1 binding sites from
iPSC-derived PPs and adult human islets, only 20.4% of the identiﬁed
PDX1 targets were common in both cell populations. Interestingly, the
function of genes near common and speciﬁc binding sites differed
markedly and reﬂects cellular function. PDX1-bound genes in islets
were related to b-cell-speciﬁc functions. For example, the Kþ channel
KCNJ11 as well as the glucose transporter SLC2A2 are essential for
adult b-cell function, whereas NKX6-1 and MAFA are important for b-
cell identity and maturation. On the other hand, in PP cells PDX1-bound
genes, such as GATA4 and ONECUT1, are associated with processes
and pathways in early pancreas development. This shows that,
depending on the developmental stage, PDX1 target sites change to
activate molecular programs that are required for stage-speciﬁc
functions.
The presence of H3K27ac in PP cells at regions carrying T2DM-
associated SNPs indicates that these regions participate in the regu-
lation of gene activity. Variation in these regions potentially interferes
with the regulation of T2DM-relevant genes at the PP stage and might
therefore impair developmental programs and lead to reduce b-cell
mass or function at birth that contributes to an increased susceptibility
to T2DM. It has been shown that b-cell mass in children is highly
variable between individuals [39] and diabetic patients show
decreased b-cell mass [40]. One of the SNPs that we detected in a PP-
speciﬁc PDX1 binding site, rs11263763, lies in the ﬁrst intron of
HNF1B and has been shown to reduce HNF1B expression [41]. This
gene has several SNPs in the ﬁrst and second intron that are linked to
T2DM. During mouse pancreatic development, Hnf1b is involved in
controlling proliferation and survival of multipotent pancreatic pro-
genitors and deletion of the gene causes pancreatic hypoplasia. Hnf1b
is also important for the speciﬁcation of endocrine progenitors through
regulation of Ngn3 expression [42]. In humans, some mutations in
HNF1B cause MODY5 [43]. We also identiﬁed the SNPs rs12762233
and rs7087006 within PP-speciﬁc PDX1 binding sites at the TCF7L2
locus. This gene, also known as Tcf4, is a member of the HMG-box
containing T-cell factor (Tiff)/Lymphoid enhancer factor (Lef) tran-
scription factor family of DNA-binding proteins and acts downstream of
the canonical Wnt pathway [44]. GWAS studies have identiﬁed TCF7L2
as the locus conveying the highest risk for developing T2DM in Eu-
ropean [45]. In mouse, Tcf7l2 is an important regulator of b-cell
development [46], whereas in human it regulates b-cell survival and
function [47]. Genetic and metabolic studies show that people carrying
TCF7L2 polymorphisms have insulin secretion defects in the presence
of normal incretin plasma levels [48]. HNF1B and TCF7L2 are therefore
important developmental regulatory factors and SNPs in PDX1-bound
regions in these loci might impair early developmental processes
that result in a higher risk to develop T2DM later in adulthood. The
three SNPs we found in islet-speciﬁc binding sites are near the FTO,
THADA, and IGF2BP2 genes, suggesting that these SNPs might
modulate adult b-cell function.
In summary, our study provides a PDX1 regulated human pancreas
developmental program that can be used to investigate the effects of
PDX1 mutations, e.g. in point mutations in the transactivation domain
found in T2DM patients, on pancreas developmental and islet PDX1
program [49,50]. Also, we ﬁnd more than 430 T2DM-associated SNPs
in active regulatory regions and 32% of T2DM genes to be bound by
PDX1 in XM001 PPs, demonstrating that PDX1 occupancy is an efﬁ-
cient way to identify important pancreatic developmental and disease
genes. This provides the base for further disease modeling in vitro
using stem cell and gene editing technologies to understand the causal
pathomechanisms underlying diabetes.s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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